Información de la revista
Vol. 22. Núm. S2.
16.º Simposio Científico Alimentación, Lípidos y Aterosclerosis
Páginas 48-51 (diciembre 2010)
Vol. 22. Núm. S2.
16.º Simposio Científico Alimentación, Lípidos y Aterosclerosis
Páginas 48-51 (diciembre 2010)
Acceso a texto completo
Efficacy and benefits of lipid-lowering drug therapy. The new European guidelines for cardiovascular disease prevention
Visitas
1060
Guy De Backer
Department of Public Health, Ghent University, Department of Cardiology, University Hospital, Ghent, Belgium
Este artículo ha recibido
Información del artículo
El Texto completo está disponible en PDF
References
[1.]
Cholesterol Treatment Trialists’Collaborators.
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90056 participants in 14 randomised trials of statins.
Lancet, 366 (2005), pp. 1267-1278
[2.]
J.C. LaRosa, S.M. Grundy, D.D. Waters, C. Shear, P. Barter, J.C. Fruchart, et al.
Intensive lipid lowering with atorvastatin in patients with stable coronary disease.
New Engl J Med, 352 (2005), pp. 1425-1435
[3.]
C.P. Cannon, E. Braunwald, C.H. McCabe, D.J. Rader, J.L. Rouleau, R. Belder, et al.
Comparison of intensive and moderate lipid lowering with statins after acute coronary syndromes.
New Engl J Med, 350 (2004), pp. 1495-1504
[4.]
T.R. Pedersen, O. Faergeman, J.J. Kastelein, A.G. Olsson, M.J. Tikkanen, I. Holme, et al.
High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomised controlled trial.
JAMA, 294 (2005), pp. 2437-2445
[5.]
C.P. Cannon, R.P. Giugliano, M.A. Blazing, R.A. Harrington, J.L. Peterson, C.M. Sisk, IMPROVE-IT Investigators, et al.
Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial). Comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes.
Am Heart J, 156 (2008), pp. 826-832
[6.]
Heart Protection Study Collaborative Group.
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatine in 20536 high-risk individuals: a randomized placebo-controlled trial.
Lancet, 360 (2002), pp. 7-22
[7.]
Heart Protection Study Collaborative Group.
MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatine in 5963 people with diabetes: a randomized placebo-controlled trial.
Lancet, 361 (2003), pp. 2005-2016
[8.]
I. Graham, D. Atar, K. Borch-Johnsen, G. Boysen, G. Burell, R. Cifkova, et al.
European Guidelines on cardiovascular disease prevention in clinical practice: executive summary.
Eur Heart J, 28 (2007), pp. 2375-2414
Copyright © 2010. Sociedad Española de Arteriosclerosis y Elsevier España S.L.